D-1611-2014 Class II Terminated

Recalled by AbbVie Inc — North Chicago, IL

FDA drug recall D-1611-2014 was initiated by AbbVie Inc on Sep 15, 2014 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000. The recall status is terminated (terminated Jun 22, 2016). Affected quantity: 18,021 Bottles.

Recall details

Product Type
Drugs
Report Date
Oct 8, 2014
Initiation Date
Sep 15, 2014
Termination Date
Jun 22, 2016
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
18,021 Bottles

Product description

CREON (pancrelipase) Delayed-Release Capsules, Lipase 24,000 USP Units, 250 Capsule Bottles, Rx Only. Marketed by: AbbVie Inc., North Chicago, IL 60064, Product of Germany. NDC 0032-1224-07.

Reason for recall

Presence of Foreign Tablets/Capsules; Presence of co-mingled LipaCreon 13000.

Distribution pattern

US: Nationwide

Code information

Lot #: 1020156; Expiry: 3/31/2016

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1611-2014
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for AbbVie Inc? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-1611-2014. Report a data issue: hello@regdatalab.com.